In an 80-year-old patient with Alzheimer disease experiencing sundowning, what medication regimen can be used to manage the symptoms?

Managing Sundowning in an 80-Year-Old with Alzheimer's Disease

Start with nonpharmacologic interventions first, and if medication becomes necessary, use low-dose trazodone (25 mg at bedtime) as the first-line agent, with melatonin (3-9 mg at bedtime) as an alternative or adjunct. 1, 2

Stepwise Approach to Management

Step 1: Implement Nonpharmacologic Strategies First

Before any medication, these environmental and behavioral modifications are essential and should be exhausted first 1:

Environmental modifications specific to sundowning:

• Increase lighting in late afternoon and evening to reduce confusion and restlessness 1
• Establish a rigid, predictable routine with meals and bedtime at the same time daily
• Reduce environmental stimulation in the evening (minimize TV noise, avoid crowded places, reduce household clutter)
• Avoid glare from windows and mirrors during evening hours

Behavioral strategies:

• Use the "three R's" approach: Repeat instructions, Reassure the patient, and Redirect to calming activities 1
• Schedule toileting to prevent discomfort-related agitation
• Ensure all comorbid medical conditions (pain, infection, constipation) are optimally treated

Step 2: Pharmacologic Management When Nonpharmacologic Measures Fail

First-line medication: Trazodone

• Start at 25 mg at bedtime 1
• Can increase gradually to 200-400 mg per day in divided doses if needed
• Particularly effective for insomnia and sundowning-related agitation
• Caution: Use carefully in patients with premature ventricular contractions 1

Alternative/Adjunct: Melatonin

• Dosing: 3-9 mg at bedtime 2, 3
• Strong evidence specifically for sundowning in Alzheimer's disease
• Improves sleep quality and suppresses sundowning behavior 2
• Excellent safety profile with minimal side effects
• Can be used long-term (studies show effectiveness for 22-35 months) 2

Consider acetylcholinesterase inhibitors if not already prescribed:

• Donepezil, rivastigmine, or galantamine may improve behavioral symptoms including sundowning 1, 4
• These address the underlying disease process and can reduce need for additional psychotropics

Step 3: Second-Line Options for Severe, Refractory Agitation

Only if sundowning involves severe psychomotor agitation, combativeness, or psychotic features that pose safety risks:

Atypical antipsychotics (use lowest effective dose):

• Quetiapine: Start 12.5 mg twice daily (more sedating, which may be beneficial for evening symptoms) 1

  • Watch for orthostatic hypotension
  • Maximum 200 mg twice daily

• Risperidone: Start 0.25 mg at bedtime 1

  • Maximum 2-3 mg per day
  • Extrapyramidal symptoms may occur at ≥2 mg per day

• Olanzapine: Start 2.5 mg at bedtime 1

  • Generally well tolerated
  • Maximum 10 mg per day

Critical safety considerations for antipsychotics:

• These carry increased mortality risk in elderly dementia patients (black box warning)
• Should be time-limited with regular reassessment for discontinuation 5
• Avoid typical antipsychotics (haloperidol, etc.) due to high risk of extrapyramidal symptoms and tardive dyskinesia (50% risk after 2 years in elderly) 1

Step 4: Avoid These Medications

Do NOT use benzodiazepines routinely:

• Lead to tolerance, addiction, cognitive impairment
• Cause paradoxical agitation in 10% of patients 1
• If absolutely necessary, use only short-acting agents (lorazepam, oxazepam) infrequently and at low doses

Monitoring and Follow-Up

• Reassess effectiveness at 2-4 weeks for behavioral interventions
• For medications, allow 4-8 weeks for full therapeutic trial 1
• Attempt dose reduction or discontinuation after 6-9 months if symptoms stabilize 5
• Monitor for medication side effects at each visit, particularly:
  • Orthostasis with quetiapine
  • Extrapyramidal symptoms with antipsychotics
  • Cardiac effects with trazodone

Key Clinical Pitfalls to Avoid

1. Starting with antipsychotics rather than environmental modifications and safer agents like trazodone or melatonin
2. Using benzodiazepines which frequently worsen confusion and increase fall risk
3. Continuing antipsychotics indefinitely without attempting discontinuation trials
4. Missing underlying medical triggers (urinary tract infection, pain, constipation, medication side effects)
5. Using typical antipsychotics (haloperidol) which have unacceptably high rates of serious adverse effects in this population 1